UK Court Clarifies Obviousness Rule In Levaquin Suit

Law360, New York (July 6, 2009, 12:00 AM EDT) -- A U.K. appeals court has upheld a determination of validity for Daiichi Pharmaceutical Co.'s patent for the active ingredient in the antibiotic Levaquin, ruling that an invention is not obvious if the course of action is obvious but a skilled person would not have the motivation to pursue it to the point of invention.

The Supreme Court of Judicature Court of Appeal on Thursday dismissed Generics (UK)'s appeal from the High Court of Justice, Chancery Division, which held in October that Daiichi's patent, European Patent Number...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.